Skip to content
    Clinical Trials

    Neoadjuvant Durvalumab With Chemotherapy Yields 74.6% Resection Rate in NSCLC

    Reck et alNature Medicine

    Neoadjuvant Durvalumab With Chemotherapy Yields 74.6% Resection Rate in NSCLC
    The phase 2 MDT-BRIDGE study (ClinicalTrials.gov identifier: NCT05925530) evaluated a multidisciplinary team (MDT)-guided strategy utilizing perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in patients with resectable or borderline resectable non-small-cell lung cancer (NSCLC). For patients found to be unresectable following neoadjuvant chemoimmunotherapy based on MDT assessment, treatment transitioned to chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen).
    A total of 142 patients received neoadjuvant treatment, with 64.8% classified as resectable and 35.2% as borderline resectable at baseline. The primary endpoint was overall resection rate, evaluated descriptively without formal hypothesis testing. Secondary endpoints included event-free survival, progression-free survival, pathological complete response rate in the resectable cohort, circulating tumor DNA clearance between baseline and presurgery/pre-CRT, and safety.
    The trial achieved an overall resection rate of 74.6% (95% CI, 66.7‒81.6). Among the 106 patients who underwent surgical intervention, the R0 resection rate was 96.2% (95% CI, 90.6‒99.0). In total, curative-intent local therapy was delivered to 92.3% of patients (n = 131), consisting of surgery in 106 patients and CRT in 25 patients. Subsequently, 82.4% of patients (n = 117) initiated durvalumab therapy in either the adjuvant setting (n = 94) or consolidation setting (n = 23).
    During adjuvant or consolidation durvalumab administration, maximum grade 3/4 adverse events were documented in 7.4% of resected patients and 17.4% of CRT-treated patients. Adverse events led to treatment discontinuation in 8.5% of the surgical group and 13.0% of the CRT group. The MDT-guided protocol was feasible, allowed the delivery of curative-intent treatment followed by durvalumab in most patients, and demonstrated encouraging preliminary efficacy with a manageable adjuvant or consolidation safety profile consistent with prior investigations.

    Key Takeaways

    • Neoadjuvant durvalumab plus chemotherapy achieved an overall resection rate of 74.6% (95% CI, 66.7‒81.6) in a cohort comprising 64.8% resectable and 35.2% borderline resectable NSCLC, with an R0 resection rate of 96.2% (95% CI, 90.6‒99.0) among patients undergoing surgery.
    • Overall, 92.3% of patients (n = 131/142) proceeded to curative-intent treatment (surgery: n = 106; chemoradiotherapy: n = 25), and 82.4% (n = 117) received adjuvant (n = 94) or consolidation (n = 23) durvalumab.
    • During adjuvant or consolidation durvalumab, grade 3/4 adverse events occurred in 7.4% of resected patients and 17.4% of chemoradiotherapy-treated patients, leading to treatment discontinuation in 8.5% and 13.0%, respectively.